Physiomics Plc (PYC) - Total Assets

Latest as of December 2025: GBX558.00K GBX ≈ $67.89 USD

Based on the latest financial reports, Physiomics Plc (PYC) holds total assets worth GBX558.00K GBX (≈ $67.89 USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See PYC book value for net asset value and shareholders' equity analysis.

Physiomics Plc - Total Assets Trend (2001–2025)

This chart illustrates how Physiomics Plc's total assets have evolved over time, based on quarterly financial data.

Physiomics Plc - Asset Composition Analysis

Current Asset Composition (June 2025)

Physiomics Plc's total assets of GBX558.00K consist of 98.2% current assets and 1.8% non-current assets.

Asset Category Amount (GBX) % of Total Assets
Cash & Equivalents GBX0.00 51.7%
Accounts Receivable GBX363.28K 40.7%
Inventory GBX0.00 0.0%
Property, Plant & Equipment GBX0.00 0.0%
Intangible Assets GBX3.28K 0.4%
Goodwill GBX0.00 0.0%

Asset Composition Trend (2001–2025)

This chart illustrates how Physiomics Plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Physiomics Plc (PYC) market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Physiomics Plc's current assets represent 98.2% of total assets in 2025, an increase from 52.5% in 2001.
  • Cash Position: Cash and equivalents constituted 51.7% of total assets in 2025, up from 34.5% in 2001.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 46.0% in 2001.
  • Asset Diversification: The largest asset category is accounts receivable at 40.7% of total assets.

Physiomics Plc Competitors by Total Assets

Key competitors of Physiomics Plc based on total assets are shown below.

Company Country Total Assets
Argen-X
F:1AE
Germany €7.18 Billion
Tubize-Fin
BR:TUB
Belgium €1.93 Billion
BrightGene Bio Medical Technology C
SHG:688166
China CN¥5.38 Billion
Dashenlin Pharm Grp Co Ltd
SHG:603233
China CN¥26.08 Billion
Staidson Beijing Biopharma
SHE:300204
China CN¥1.26 Billion
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
China CN¥6.64 Billion
Ardelyx Inc
NASDAQ:ARDX
USA $486.17 Million
Xiangxue Pharmaceutical
SHE:300147
China CN¥7.36 Billion

Physiomics Plc - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.30 4.77 11.35
Quick Ratio 3.30 4.77 11.35
Cash Ratio 0.00 0.00 0.00
Working Capital GBX380.00K GBX400.00K GBX1.26 Million

Physiomics Plc - Advanced Valuation Insights

This section examines the relationship between Physiomics Plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 5.25
Latest Market Cap to Assets Ratio 0.03
Asset Growth Rate (YoY) 111.1%
Total Assets GBX892.03K
Market Capitalization $27.57K USD

Valuation Analysis

Below Book Valuation: The market values Physiomics Plc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Physiomics Plc's assets grew by 111.1% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Physiomics Plc (2001–2025)

The table below shows the annual total assets of Physiomics Plc from 2001 to 2025.

Year Total Assets Change
2025-06-30 GBX892.03K
≈ $108.53
+111.08%
2024-06-30 GBX422.60K
≈ $51.42
-37.34%
2023-06-30 GBX674.39K
≈ $82.05
-39.54%
2022-06-30 GBX1.12 Million
≈ $135.71
-15.71%
2021-06-30 GBX1.32 Million
≈ $161.01
-8.52%
2020-06-30 GBX1.45 Million
≈ $176.00
+108.34%
2019-06-30 GBX694.29K
≈ $84.47
-15.15%
2018-06-30 GBX818.23K
≈ $99.56
+97.08%
2017-06-30 GBX415.18K
≈ $50.51
+36.88%
2016-06-30 GBX303.31K
≈ $36.90
-19.94%
2015-06-30 GBX378.87K
≈ $46.10
+55.15%
2014-06-30 GBX244.19K
≈ $29.71
-35.82%
2013-06-30 GBX380.47K
≈ $46.29
-54.71%
2012-06-30 GBX840.10K
≈ $102.22
-3.21%
2011-06-30 GBX868.00K
≈ $105.61
-5.86%
2010-06-30 GBX922.00K
≈ $112.18
+235.27%
2009-06-30 GBX275.00K
≈ $33.46
+141.23%
2008-06-30 GBX114.00K
≈ $13.87
-62.38%
2007-06-30 GBX303.00K
≈ $36.87
+107.53%
2006-06-30 GBX146.00K
≈ $17.76
-72.30%
2005-06-30 GBX527.00K
≈ $64.12
+466.67%
2004-06-30 GBX93.00K
≈ $11.32
+17.72%
2003-06-30 GBX79.00K
≈ $9.61
-43.17%
2001-06-30 GBX139.00K
≈ $16.91
--

About Physiomics Plc

LSE:PYC UK Biotechnology
Market Cap
$27.57K
GBX226.60 Million GBX
Market Cap Rank
#31193 Global
#1245 in UK
Share Price
GBX0.50
Change (1 day)
+0.00%
52-Week Range
GBX0.27 - GBX0.65
All Time High
GBX17.13
About

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour pred… Read more